Big Pharma is investing heavily in AI to slash development timelines and foster innovation. | Big Pharma is investing heavily ...

Frazier Life Sciences has sourced a further $630 million for its fund focused on small and mid-cap biotechs. | Frazier Life ...

The COVID-19 pandemic made the public acutely aware of how vulnerable their noses are. | The COVID-19 pandemic made us ...

Triveni Bio has roped in $115 million in series B funds to advance preclinical antibody programs designed to treat ...

Zephyrm Bioscience is gusting toward the Hong Kong stock exchange, filing (PDF) for an IPO to bankroll phase 3 trials of its ...

Lundbeck has tapped Charles River Laboratories’ artificial intelligence capabilities to aid the discovery of neuroscience ...

Synchron has reported that its miniature brain-computer interface implant, threaded up through the blood vessels to help read the activity of the motor cortex, showed no major side effects in a ...

Gritstone bio has brought in bankers to explore “potential value-maximizing strategies” after its phase 2 colorectal cancer ...

Cardia’s ShortCut device, designed to open up previously implanted heart valves and clear a path for blood to flow into the ...

With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...

Antibiotics are one of the most common medicines in the world, with about 236 million prescriptions in the U.S. | The company ...

Shattuck Labs has hammered another nail into the coffin of CD47. After seeing a “modest” effect on survival in blood cancer, ...